ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

Rhea-AI Summary

ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on protecting patients from severe allergic reactions and anaphylaxis, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Conference.

The company's leadership, including Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas, will engage in a fireside chat on February 12, 2025, at 2:40 p.m. ET. The conference will be held virtually, and management will also conduct one-on-one meetings with investors.

A live webcast of the fireside chat will be accessible online and through the company's website's Investors & Media section. The webcast recording will remain available for 90 days on the company's website.

News Market Reaction

+1.84%

1 alert

+1.84% News Effect

On the day this news was published, SPRY gained 1.84%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Oppenheimer 35^th Annual Healthcare Conference being held virtually.

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Wednesday, February 12, 2025, at 2:40 p.m. ET. Company management will also participate in one-on-one meetings with investors.

A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® 2 mg (trade name EURneffy^® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com

ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com

FAQ

When is ARS Pharmaceuticals (SPRY) presenting at the Oppenheimer Healthcare Conference?

ARS Pharmaceuticals will present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, at 2:40 p.m. ET.

How can investors access the SPRY fireside chat at the Oppenheimer Conference?

Investors can access the fireside chat through a live webcast available on the company's website in the Investors & Media section.

How long will the SPRY Oppenheimer Conference presentation replay be available?

The webcast replay will be archived on the company's website for 90 days following the presentation.

Which executives from SPRY will participate in the Oppenheimer Healthcare Conference?

Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will participate in the conference.

Will SPRY management be available for individual investor meetings at the Oppenheimer Conference?

Yes, company management will participate in one-on-one meetings with investors during the conference.